|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.380 USD | -7.65% |
|
-16.13% | -70.99% |
| 08-14 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-14 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 336M | - | - | - | ||
| 63.77B | |||||
| 56.37B | |||||
| 54.62B | |||||
| 44.06B | |||||
| 42.11B |
Select your edition
All financial news and data tailored to specific country editions
